Pharmacokinetics and tissue distribution of metronidazole in the new born infant.
Metronidazole pharmacokinetics and tissue distribution were studied in 11 infants varying in gestational age from 28 to 40 weeks. Elimination half-life was inversely related to gestational age, and ranged from 22.5 to 109 hours. Hepatic hydroxylation of metronidazole was not evident in infants less than 35 weeks' gestation, unless they had been exposed prenatally to betamethasone. A dosage schedule of 15 mg/kg intravenously as an initial single dose is proposed, and will provide adequate therapeutic levels for 48 hours in the preterm infant and for 24 hours in the term infant. Subsequently a dose of 7.5 mg/kg/12 hours is suggested for the first week of life.
D001424:Bacterial Infections / Q000188:drug therapy*; D001623:Betamethasone / Q000627:therapeutic use; D005260:Female; D005865:Gestational Age; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000378:metabolism*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D014018:Tissue Distribution
D008795:Metronidazole; D001623:Betamethasone